Literature DB >> 6836653

Mechanisms of relaxant action of nicardipine, a new Ca++-antagonist, on isolated dog cerebral and mesenteric arteries.

M Yamamoto, T Ohta, N Toda.   

Abstract

In helically-cut strips of cerebral and mesenteric arteries contracted with prostaglandin (PG) F2 alpha, carbocyclic thromboxane A2 (cTxA2) or K+, the addition of nicardipine caused a dose-related relaxation. Nicardipine-induced relaxation was greater in cerebral than in mesenteric arteries when contracted with PGF2 alpha and cTxA2, but did not appreciably differ in the arteries contracted with K+. Cerebral arteries contracted with hemolysate and PGF2 alpha relaxed in response to nicardipine to a similar extent. The contractile response to PGF2 alpha was attenuated by pretreatment with nicardipine, the attenuation being greater in cerebral than in mesenteric arteries. Ca++-induced contractions in cerebral and mesenteric arteries previously exposed to Ca++-free media and depolarized by excess K+ were attenuated by nicardipine to a similar extent. PGF2 alpha-induced contractions of cerebral arteries exposed to Ca++-free media were attenuated by nicardipine, whereas those of mesenteric arteries were unaffected. Attenuations by nicardipine of the Ca++-induced contraction in PGF2 alpha-treated cerebral arteries were greater than those seen in mesenteric arteries. It may be concluded that nicardipine produces a greater relaxation of cerebral arteries than mesenteric arteries, possibly due to a greater inhibition of the Ca++-influx and to a decrease in the release of Ca++ from intracellular storage sites in cerebral arteries. As far as the concentrations used are concerned, nicardipine appears to attenuate the inward movement of Ca++ across cell membrane in mesenteric arterial smooth muscle, but not the release of intracellularly stored Ca++.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6836653     DOI: 10.1161/01.str.14.2.270

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  8 in total

1.  Correlation of intraventricular nicardipine for refractory vasospasm in aneurysmal subarachnoid hemorrhage with improved neurophysiology on intracranial multimodality monitoring: illustrative case.

Authors:  Ramesh Grandhi; Sarah T Menacho; Vijay M Ravindra; Chad Condie; Philipp Taussky; Gregory W J Hawryluk
Journal:  J Neurosurg Case Lessons       Date:  2022-05-30

Review 2.  Vasodilators during cerebral aneurysm surgery.

Authors:  K Abe
Journal:  Can J Anaesth       Date:  1993-08       Impact factor: 5.063

3.  Endothelins: vasoconstrictor effects and localization in canine cerebral arteries.

Authors:  A Saito; R Shiba; M Yanagisawa; T Masaki; S Kimura; K Yamada; T Mima; T Shigeno; K Goto
Journal:  Br J Pharmacol       Date:  1991-05       Impact factor: 8.739

Review 4.  Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

5.  A randomized double-blind crossover study of nicardipine and nifedipine in patients with angina pectoris and concomitant essential hypertension.

Authors:  M Metra; S Nodari; G Nordio; L Bonandi; R Raddino; P Feroldi; L Dei Cas; O Visioli
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

6.  Cardiovascular pharmacology of nicardipine in animals.

Authors:  T Takenaka; M Asano; K Shiono; M Shibasaki; O Inagaki
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

7.  Indirect portography enhanced by nicardipine versus prostaglandin E1.

Authors:  Y Inoue; H Nakamura; H Akaji; K Yamasaki
Journal:  Cardiovasc Intervent Radiol       Date:  1995 Mar-Apr       Impact factor: 2.740

8.  Nicardipine: pharmacokinetics and effects on carotid and brachial blood flows in normal volunteers.

Authors:  C Thuillez; M Gueret; P Duhaze; F Lhoste; J R Kiechel; J F Giudicelli
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.